Non-Hodgkins Lymphoma Treatment Market By Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy), By Application (Hospital, Cancer Clinics, Home Care), By End-User (Oncologists, Hematologists, General Physicians), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Non-Hodgkins Lymphoma Treatment Market was valued at USD 10.6 billion in 2024-e and will surpass USD 17.9 billion by 2030; growing at a CAGR of 9.2% during 2025 - 2030.

The Non-Hodgkin’s lymphoma (NHL) treatment market is witnessing substantial growth, driven by advancements in targeted therapies and immunotherapies that offer more personalized treatment options for patients. Non-Hodgkin’s lymphoma, a type of cancer that originates in the lymphatic system, has seen significant improvements in treatment outcomes over the years. Chemotherapy, radiation therapy, and more recently, immunotherapy and targeted therapies, are increasingly becoming the standard of care for NHL patients. The market is expanding as the demand for more effective and less toxic treatment alternatives rises.

Furthermore, increased awareness of early detection, along with a growing number of clinical trials and advancements in biologics, is contributing to the overall growth of the NHL treatment market. The rise in NHL cases globally, coupled with innovations in treatment modalities, is expected to further boost the market. The demand for personalized medicine, where treatment is tailored to the individual’s genetic makeup, is also becoming a significant driver, as it promises improved treatment outcomes and fewer side effects.

Chemotherapy Remains the Largest Treatment Option Owing to Established Efficacy

Chemotherapy remains the largest treatment type in the Non-Hodgkin’s lymphoma market owing to its long-established efficacy and widespread use in various NHL subtypes. Despite the emergence of newer therapies, chemotherapy continues to be the go-to treatment for many NHL patients due to its proven effectiveness in targeting rapidly dividing cancer cells. Chemotherapy regimens such as CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) and R-CHOP (which includes Rituximab) are commonly used and have demonstrated significant success in treating a wide range of NHL cases.

Additionally, chemotherapy is typically used in combination with other treatments, such as immunotherapy, to enhance the overall treatment response. While newer treatments are gaining traction, chemotherapy remains indispensable, particularly in cases of aggressive NHL or when other therapies may not be viable. This is why chemotherapy continues to hold the largest market share in NHL treatment. However, with the growing emphasis on reducing side effects and improving patient quality of life, the market is also witnessing a shift towards more targeted and personalized therapies.

Immunotherapy is Fastest Growing Treatment Owing to High Efficacy and Low Side Effects

Immunotherapy is the fastest growing treatment modality in the Non-Hodgkin’s lymphoma market, owing to its promising efficacy and favorable side-effect profile. Immunotherapy leverages the patient’s immune system to target and kill cancer cells, offering a more targeted approach compared to traditional treatments like chemotherapy. Monoclonal antibodies such as Rituximab, which is used to treat various subtypes of NHL, have revolutionized the treatment landscape by providing long-term remission for many patients with relatively fewer side effects.

CAR-T cell therapy, another form of immunotherapy, has shown remarkable promise in treating relapsed or refractory NHL. This innovative treatment involves modifying the patient’s own T-cells to better recognize and attack cancer cells. As the technology continues to advance, the number of clinical approvals for immunotherapies targeting different types of NHL is increasing. The rise in immunotherapy treatments is driving the fastest growth in the NHL treatment market, as more patients benefit from these groundbreaking therapies that offer a higher quality of life and reduced treatment-associated complications.

Oncologists are the Largest End-User Group Owing to Central Role in NHL Treatment

Oncologists are the largest end-user group in the Non-Hodgkin’s lymphoma treatment market due to their central role in diagnosing and managing cancer treatments. Oncologists, particularly hematologic oncologists, are responsible for developing personalized treatment plans based on the specific subtype of NHL, the patient’s medical history, and the progression of the disease. As experts in cancer care, oncologists are typically the primary healthcare professionals who prescribe chemotherapy, targeted therapies, immunotherapy, and radiation treatments to NHL patients.

The role of oncologists in managing complex cases, particularly in aggressive forms of NHL, is critical, as they can recommend a combination of treatments or clinical trials that offer the best chance for remission. Their expertise in the latest treatment modalities, including biologic therapies and novel immunotherapies, positions them as key decision-makers in the NHL treatment journey. Consequently, oncologists continue to be the largest consumer group for NHL treatment drugs and therapies, driving market growth in the sector.

North America is the Largest Region Owing to Advanced Healthcare Infrastructure

North America is the largest region in the Non-Hodgkin’s lymphoma treatment market, owing to its advanced healthcare infrastructure, widespread access to cutting-edge treatment options, and high healthcare spending. The United States, in particular, is a major market player, with a high incidence rate of NHL and an extensive network of specialized cancer treatment centers. The availability of advanced diagnostic tools and a growing number of clinical trials for new treatments have positioned North America as the dominant region for NHL treatment.

Moreover, the strong presence of pharmaceutical companies and research institutions in North America contributes significantly to the development and commercialization of innovative therapies, particularly in immunotherapy and targeted treatments. As a result, North America is expected to maintain its leadership in the NHL treatment market, with continued growth driven by advancements in technology, higher treatment adoption rates, and strong regulatory support for new therapies.

Competitive Landscape

The Non-Hodgkin’s lymphoma treatment market is highly competitive, with several pharmaceutical giants leading the way in terms of product development and market share. Key players in the market include Roche, Bristol-Myers Squibb, Novartis, and Gilead Sciences, all of which offer a range of therapies aimed at treating NHL. These companies are focusing on expanding their product portfolios by investing in clinical research and collaborating with academic institutions to bring innovative treatments to market.

The market is seeing increased competition in the immunotherapy segment, particularly with the rise of CAR-T cell therapies, which have shown transformative potential for relapsed or refractory cases. Additionally, partnerships and acquisitions are common as companies seek to broaden their therapeutic offerings and maintain their competitive edge. As treatment approaches for NHL continue to evolve, the market will remain dynamic, with ongoing research and development efforts aimed at improving patient outcomes and expanding access to innovative therapies.

Recent Developments:

• In December 2024, Roche Holding AG launched a new immunotherapy drug targeting relapsed Non-Hodgkin’s lymphoma, showing promising results in clinical trials.
• In November 2024, Novartis International AG received FDA approval for a new CAR-T cell therapy for treatment-resistant Non-Hodgkin’s lymphoma.
• In October 2024, Bristol-Myers Squibb announced the expansion of its targeted therapy portfolio for Non-Hodgkin’s lymphoma treatment.
• In September 2024, Gilead Sciences, Inc. completed a successful phase 3 trial for its new monoclonal antibody therapy for Non-Hodgkin’s lymphoma.
• In August 2024, Celgene Corporation entered into a strategic partnership with a leading hospital network to expand its lymphoma treatment options.

List of Leading Companies:

• Roche Holding AG
• Novartis International AG
• Bristol-Myers Squibb Company
• Celgene Corporation
• Gilead Sciences, Inc.
• Amgen Inc.
• Merck & Co., Inc.
• Pfizer, Inc.
• AbbVie Inc.
• GlaxoSmithKline plc
• Eli Lilly and Company
• Johnson & Johnson
• Takeda Pharmaceutical Company Limited
• Regeneron Pharmaceuticals, Inc.
• Kite Pharma (a Gilead Company)

Report Scope: